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Glioblastoma multiforme (GBM) is the most common and lethal
primary brain cancer that is driven by aberrant signaling of growth
factor receptors, particularly the epidermal growth factor receptor
(EGFR). EGFR signaling is tightly regulated by receptor endocytosis
and lysosome-mediated degradation, although the molecular
mechanisms governing such regulation, particularly in the context
of cancer, remain poorly delineated. Here, high-resolution ge-
nomic proﬁles of GBM identiﬁed a highly recurrent focal 1p36
deletion encompassing the putative tumor suppressor gene, Mig-
6. We show that Mig-6 quells the malignant potential of GBM cells
and dampens EGFR signaling by driving EGFR into late endosomes
and lysosome-mediated degradation upon ligand stimulation.
Mechanistically, this effect is mediated by the binding of Mig-6
to a SNARE protein STX8, a protein known to be required for late
endosome trafﬁcking. Thus, Mig-6 functions to ensure recruitment
of internalized receptor to late endosomes and subsequently the
lysosomal degradation compartment through its ability to specif-
ically link EGFR and STX8 during ligand-stimulated EGFR trafﬁck-
ing. In GBM, the highly frequent loss of Mig-6 would therefore
serve to sustain aberrant EGFR-mediated oncogenic signaling.
Together, these data uncover a unique tumor suppression mecha-
nism involving the regulation of receptor trafﬁcking.
glioblastoma | vesicle | STX8
Glioblastoma multiforme (GBM) is the most aggressive formof malignant glioma and stands as one of the most lethal
cancers with median survival of ≈12–15 months (1). Extensive
molecular and genomic studies of human glioma have identiﬁed
numerous genetic and genomic alterations resulting in activation
of multiple receptor tyrosine kinases, most notably epidermal
growth factor (EGFR), which is found to be ampliﬁed and
overexpressed in ∼45% of primary GBMs, although much less
frequently in low-grade gliomas (2, 3). Clinically, overexpression
of EGFR has been correlated with poor prognosis in GBM
patients (4), and the precise wiring of the EGFR network and
the regulation of its signaling pathway in GBM have always been
an area of active investigation. It is well known that multiple
mechanisms are engaged in the activation of the EGFR pathway
during tumor initiation and progression, including receptor
ampliﬁcation and activating receptor mutations (5). Intriguingly,
EGFR mutations occurring in GBM often involve the deletions
in the extracellular domain or cytoplasmic tails, such as the
EGFRvIII mutant missing the extracellular ligand binding
domain (5), whereas EGFR kinase domain mutations commonly
found in nonsmall cell lung cancer (NSCLC) are rare in GBM,
suggesting distinctive oncogenic EGFR networks in different
tumor types.
A hallmark feature of malignant glioma is its rampant genomic
instability accompanied by numerous recurrent chromosomal
structural aberrations that serve as a key pathological driving
force for tumor progression and many of them remain to be
characterized (6, 7). GBM possesses a highly rearranged genome
and high-resolution genome analysis has uncovered myriad
somatic alterations on the genomic and epigenetic levels (2, 3).
Here, using an integrated genomic and functional analysis, we
have identiﬁed Mig-6 as a candidate tumor suppressor that
regulates EGFR trafﬁcking and turnover in GBM cells. Mig-6
was originally identiﬁed as a mitogen-inducible gene and has
been implicated in the feedback regulation of a variety of sig-
naling processes, including the EGFR pathway (8–11). Ablation
of Mig-6 was shown to induce tumor formation in various tissues,
supporting the tumor suppressor function of Mig-6 (12–14).
However, the role of Mig-6 during gliomagenesis is largely
unknown. We report that Mig-6 functions to suppress the
malignant potential of GBM cells by enhancing EGFR trafﬁck-
ing into late endosomes/lysosomes and promoting its degrada-
tion. Further molecular and cell biology studies identiﬁed STX8,
a SNARE protein required for late-endosome fusion (15–17), as
a Mig-6-binding protein to form a complex with EGFR during
receptor trafﬁcking. The strong interaction between Mig-6 and
STX8 upon ligand activation therefore ensures recruitment of
internalized EGFR to late endosomes and subsequently the
lysosomal degradation compartment.
Results
Genomic analysis of GBM has revealed myriad alterations with
uncertain pathogenetic signiﬁcance. Recurrent deletion of
chromosome 1p36 is among the most common genomic events in
multiple tumor types (18–23), although the structural complexity
of these deletions and the uncertain deﬁnition of the commonly
targeted region have hampered deﬁnitive identiﬁcation of
potential tumor suppressor(s) (24). In recent high-resolution
array comparative genomic hybridization (CGH) analysis of
GBM (18 tumors, 20 cell lines) that showed recurrent 1p36
deletion (Fig. 1A, 5/38; 13.2%), we delineated a unique 270-kb
minimal common region (MCR) of deletion containing only two
known genes, PARK7 and Mig-6 (ERRFI1) (Fig. 1A), and
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showing corresponding decrease in the expression of these genes
in samples with genomic deletion (Fig. 1B). Consistent with our
data, The Cancer Genome Atlas (TCGA) dataset conﬁrmed
recurrent deletion of this region (62/339; 18.3%) that deﬁned an
MCR containing seven known genes including PARK7 andMig-6
(Fig. S1). Most notably, Mig-6 expression is down-regulated at
bothmRNAand protein levels in∼50%of primary tumor samples
and GBM cell lines, some of which do not show genomic deletion
of Mig-6, indicating that additional mechanisms ensure Mig-6
down-regulation in human GBM (Fig. 1 D and E). Whereas
PARK7 is an oncogene that inhibits the PTEN tumor suppressor
(25–27), Mig-6 shows many properties consistent with a tumor
suppressor role including cancer-prone phenotypes in knockout
mice (12, 13, 28). In the context of this study, it is notable that
Mig-6 was identiﬁed as a mitogen-inducible gene and is a pre-
sumed adaptor protein linked to the regulation of a variety of sig-
naling pathways, including the key GBM oncogene EGFR (8–11).
This proﬁle prompted us to assess the functional relevance of
Mig-6 and determine its mechanism of action in GBM.
Reconstituting Mig-6 in LN319 and LN464 cells, two GBM
cell lines that lack Mig-6 protein expression (Fig. 1 C–E), inhibits
cellular proliferation as well as anchorage-independent growth
(Fig. 2 A, B, and D), a hallmark for cellular transformation.
Conversely, the shRNA-mediated knockdown of Mig-6 (shMig-
6-1, 90% suppression) in U87 cells results in increased cell
proliferation and anchorage-independent growth and invasion
relative to control and ineffective Mig-6 shRNAs (e.g., shMig-
6-2) (Fig. 2 C, E, and F). Mig-6 knockdown in additional GBM
cells also promotes anchorage-independent growth (Fig. S2 A
and B). Consistently, these shMig-6-1 cellular phenotypes are not
elicited in LN319 cells carrying a homozygous 1p36 deletion
(Fig. 2G), indicating that the effects of Mig-6 depletion are
speciﬁc and not due to off-target effects. In addition, shMig-6-1-
induced anchorage-independent growth is suppressed in U87
cells by expression of shRNA-resistant Mig-6 (Fig. S2C, Fig. 2H).
Together, these gain- and loss-of-function studies demonstrate
that Mig-6 functions as a potent tumor suppressor and is a key
target of the 1p36 deletion event in GBM.
As a signature event in GBM, EGFR is ampliﬁed and mutated
in 50% of GBM, highlighting its oncogenic role during GBM
progression. Mig-6 has been shown to function as a feedback
inhibitor of EGFR signaling (28, 29). Moreover, studies in
human cancer cells as well as mouse models implicate that Mig-6
is a tumor suppressor of ErbB receptor-dependent carcino-
genesis (12, 30). Thus, we examined the impact of Mig-6 on
EGFR signaling in GBM cells. Consistent with previous reports
(29, 31), Mig-6 knockdown in U87 cells enhances EGFR phos-
phorylation in response to EGF and downstream activation of
MEK-ERK signaling (Fig. 3A). Similarly, Mig-6 reconstitution
in LN319 cells inhibits the activation of the EGFR pathway
Fig. 1. Mig-6 is deleted in GBM cell lines and tumor samples. (A) Array-CGH
heat map detailing Mig-6 deletion at chromosome 1p36 in primary GBM
tumor specimens. Regions of ampliﬁcation and deletion are denoted in red
and blue, respectively. (B) mRNA expression levels of PARK7 and Mig-6 in
normal human astrocytes (NHA) and LN319 cells. (C) FISH analysis of Mig-6
deletion in the GBM cell line, LN319. The green signals (arrows) indicate
hybridization using a Mig-6-speciﬁc BAC probe, whereas the red signals
indicate hybridization using a chromosome 1-speciﬁc centrosome reference
probe. (D) mRNA level of Mig-6 in NHA and GBM cell lines. (E) Mig-6 protein
level analyzed by Western blot in NHA and GBM cell lines.
Fig. 2. Mig-6 functions as a tumor suppressor. ReconstitingMig-6 expression
in (A) LN319 or (B) LN464 cells inhibits cell proliferation. Vec, empty vector
control. (C) Knockdown of Mig-6 expression in U87 cells (Inset) accelerates
cellular proliferation. shSC, hairpin control. (D) (Left) Reconstitution of Mig-6
expression in LN319 or LN464 cells attenuates anchorage-independent
growth in soft agar. (Right) Histogram quantiﬁcation. Error bars indicate ±SD
[**, P = 0.002 (LN319) and 0.008 (LN464), n = 3]. (E) (Upper) Knockdown of
Mig-6 expression in U87 cells promotes anchorage-independent growth in
soft agar. (Lower) Histogram quantiﬁcation. Error bars indicate ±SD (**, P =
0.001, n = 3). (F) Knockdown of Mig-6 expression in U87 cells promoted cell
invasion in a Boyden chamber assay. (Upper) Representative images show the
invasion of U87 cells expressing control (shSC and shMig-6-2) and targeting
shRNA (shMig-6-1) after 16-h induction with 10% FBS followed by crystal
violet (0.2%) staining. (Lower) Histogram quantiﬁcation. Error bars indicate±
SD (**, P = 0.003, n = 3). (G) shRNA targeting Mig-6 has no effect on soft
agar growth of LN319 cells. (H) Reconstitution of Mig-6 expression inhibits
soft agar growth of U87 cells expressing Mig-6 targeting shRNA (shMig-6-1).
Error bars indicate ±SD (*, P = 0.03; **, P = 0.01; n = 3).
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(Fig. 3B), indicating that Mig-6 functions to limit the activation
of EGFR signaling in these cells. Interestingly, Mig-6 over-
expression fails to inhibit EGFRvIII signaling, a constitutively
active EGFR mutant commonly found in GBM (32), in both
murine astrocytes and the human GBM cell line, even though
Mig-6 binds to EGFRvIII independent of ligand induction (Fig.
S3), suggesting direct interaction of Mig-6 may not be sufﬁcient
to suppress EGFR signaling. In agreement with this notion,
expression of Mig-6 showed a diminished inhibitory effect on the
soft-agar growth of LN319 cells expressing EGFRvIII whereas
the anchorage-independent growth of cells expressing wild-type
EGFR was dramatically suppressed by Mig-6 (Fig. S4).
Rapid EGFR internalization and degradation in response to
EGF serves as a major negative feedback regulatory mechanism
to control the duration and intensity of EGFR signaling (33, 34).
Importantly, in contrast to wild-type EGFR, the EGFRvIII
mutant does not undergo ligand-induced internalization and the
subsequent lysosome-mediated degradation (35, 36), suggesting
that Mig-6 may regulate EGFR endo/lysosomal trafﬁcking and/
or degradation. Indeed, shRNA depletion of Mig-6 in U87 cells
results in delayed EGFR turnover upon EGF treatment whereas
expression of Mig-6 in LN319 cells reduces the half-life of EGF-
activated EGFR (Fig. 3 C–F). Consistent with our ﬁnding that
Mig-6 failed to regulate EGFRvIII signaling, the half-life of
EGFR vIII is not affected in the presence of Mig-6 (Fig. S5).
Together, these data indicate that Mig-6 functions to desensitize
EGFR signaling, possibly by promoting ligand-induced degra-
dation of EGFR in GBM cells.
Given the evidence that Mig-6 enhances EGFR degradation,
we next used confocal microscopy to examine whether Mig-6
controls receptor trafﬁcking through endo-lysosomal compart-
ments in LN319 cells expressing ectopic Mig-6 and U87 depleted
of Mig-6. Indeed, the ligand stimulation by EGF strongly pro-
motes the colocalization of endogenous Mig-6 with EGFR in
vesicle structures (Fig. 4A) in U87 cells. Under these conditions,
increased colocalization of Mig-6 with the late endosomal
marker CI-M6PR (37) was noted in U87 cells treated with EGF
for 30 min (Fig. 4B). In contrast, PDGFRβ did not colocalize
with Mig-6 in PDGF-BB-treated U87 cells (Fig. S6), indicating
that Mig-6 does not play a general role for receptor degradation.
Interestingly, the colocalization of EGFR with early endosome
antigen (EEA1), a marker for early endosomes, in response to
EGF is comparable in Mig-6-depleted 87 cells, LN319 cells
overexpressing Mig-6, and their respective control cells, indi-
cating that Mig-6 does not regulate receptor trafﬁc through early
endosomes (Fig. 4 C and D). To determine whether Mig-6
controls subsequent EGFR trafﬁcking to late endosomes, we
performed receptor colocalization studies in Mig-6-depleted
U87 cells and LN319 cells overexpressing Mig-6. As expected, we
showed reduced colocalization of the EGFR with the CI-M6PR
in Mig-6-depleted U87 cells relative to cells transduced with
control siRNA (8.6% vs. 23.6%) (Fig. 4E). Similarly, recon-
stitution of Mig-6 in LN319 cells promoted EGFR trafﬁcking to
late endosomes compared to control cells (21% vs. 12.3%) (Fig.
4F). Consistent with a role for Mig-6 in late endosomal EGFR
trafﬁcking, receptor colocalization with the lysosomal marker
LAMP1 is reduced in Mig-6-depleted U87 cells and increased in
LN319 cells expressing Mig-6 (Fig. 4 G and H). Together, these
data indicate a requirement for Mig-6 in the lysosomal degra-
dation of EGFR and termination of receptor signaling by
ensuring the trafﬁcking of activated EGFR into late endosomes.
Regulation of receptor transit through endocytic compart-
ments is under tight spatial and temporal control and remains an
area of active investigation. To gain mechanistic insight into Mig-
6-regulated EGFR degradation, we screened for Mig-6-interact-
ing proteins using high-throughput yeast two-hybrid technology
(Table S1). Most notable among the recurrent Mig-6-interacting
proteins (7 of 74 positive colonies) was the t-SNARE Syntaxin 8
(STX8). STX8 is localized in the endosomal compartments and
regulates the trafﬁcking of EGFR from early to late endosomes
(15–17). We ﬁrst conﬁrmed the interaction between endogenous
Mig-6 and STX8 by coimmunoprecipitation using U87 cell lysates
(Fig. 5A), an interaction enhanced by EGF treatment (Fig. 5B).
Consistently, we detected colocalization of Mig-6 and STX8 in
vesicular compartments 30 min after EGF treatment (Fig. 5C).
Moreover, the binding of EGFR to STX8 is greatly enhanced in
the presence of Mig-6 (Fig. 5D), indicative of a trimeric complex
containing EGFR, Mig-6, and STX8. Consistent with this tenet,
EGF-induced EGFR and STX8 colocalization decreased in Mig-
6-depleted U87 cells (Fig. 5E). Together, these data strongly
indicate that Mig-6 promotes the formation of a complex con-
taining ligand-activated EGFR and STX8. Because STX8 is
important for the fusion and trafﬁcking of late endosomes (15,
17), we next examined whether STX8 is required for Mig-6-
mediated EGFR trafﬁcking to late endosomes. Knockdown of
STX8 in U87 cells (Fig. S7A) signiﬁcantly decreased the transit of
EGFR into late endosomes (Fig. 5F). More importantly, the
enhanced recruitment of EGFR to late endosomes by Mig-6 in
LN319 cells was blocked by shRNA depletion of STX8 (Fig. S7B,
Fig. 5G), indicating that STX8 is critical for Mig-6-mediated
EGFR trafﬁcking to late endosomes. Thus, Mig-6 functions via
STX8 to enhance EGF-induced receptor degradation by regu-
lating the trafﬁcking of internalized EGFR into late endosomes
and subsequent lysosomes (Fig. 5H).
Fig. 3. Mig-6 suppresses EGFR signaling and promotes ligand-induced
receptor degradation. (A) Knockdown of Mig-6 expression in U87 cells
enhances the activation of EGFR and the downstream signaling pathway in
response to EGF treatment. Cells were treated with EGF (20 ng/mL) for the
indicated times and cell lysates were immunoblotted with the indicated
antibodies. (B) Reconstitution of Mig-6 expression in LN319 cells attenuates
the activation of EGFR and the downstream signaling pathway in response
to EGF treatment. Cells were treated with EGF (20 ng/mL) for the indicated
times and cell lysates were immunoblotted with the indicated antibodies. (C)
Knockdown of Mig-6 expression in U87 cells delayed EGFR degradation
induced by EGF stimulation. Cells were pretreated with cycloheximide (CHX)
(10 μg/mL) for 1 h before being treated with EGF (20 ng/mL) in the presence
of CHX for the indicated times and cell lysates were subjected to immuno-
blotting with the indicated antibodies. (D) Histogram quantiﬁcation of EGFR
level (normalized with actin level) in C. (E) Reconstitution of Mig-6 expres-
sion in LN319 cells promotes EGFR degradation induced by EGF stimulation.
Cells were treated as described in C and lysates were subjected to immu-
noblotting with the indicated antibodies. (F) Histogram quantiﬁcation of
EGFR level (normalized with actin level) in E.
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Discussion
Many molecular genetic and histopathological studies, together
with recent large-scale cancer genome sequencing projects, have
identiﬁed EGFR and its downstream signaling networks as one
of the most deregulated components of human GBM and other
cancers (1–3). Here, by using unbiased genome-scale analysis, we
have identiﬁed Mig-6 as a key tumor suppressor in GBM that
functions as a negative regulator for EGFR signaling.
Multiple mechanisms can result in activation of the EGFR
pathway during the initiation and development ofGBM, including
increased EGFR expression, enhanced autocrine signaling, and
EGFR mutations (5). EGFR mutations commonly found in
glioma typically involve the extracellular domains, such as the
EGFRvIII mutant, as well as C-terminal deletion of the EGFR
distal to the kinase domain (2). Those mutations also inhibit the
receptor endocytosis and trafﬁcking and thus stabilize the mutant
receptor (35, 36, 38), underscoring the importance of the dereg-
ulation of the vesicle trafﬁcking pathway as a mechanism for
EGFR-mediated gliomagenesis. Although several regulators of
the receptor trafﬁcking pathway, such asCbl, have been implicated
in a number of human cancer types (39), the role of additional
trafﬁcking components during glioma development remains
largely unexplored. Our data indicate Mig-6 promotes EGFR
turnover through its regulation of the vesicle trafﬁcking pathway.
The identiﬁcation of complex formation with STX8, a SNARE
family protein important for the fusion of late endosomes, is
unique and provides a mechanistic insight into how Mig-6 modu-
lates sorting of EGFR to late endosome–lysosome compartments
upon ligand activation. Our ﬁndings that endocytic trafﬁcking and
degradation of EGFRare closely controlled byMig-6 indicate that
the antagonistic effects ofMig-6 are exerted throughperturbations
in EGFR localization that alter the duration of EGFR signaling.
As a consequence, Mig-6 deﬁciency in tumor cells further con-
tributes to the “ampliﬁcation” of EGFR signals during the
development of GBM. Consistent with this notion, in the analysis
of a total of 337 GBM samples from the TCGA dataset, we
observed a positive correlation between the genomic alterations of
Mig-6 and EGFR ampliﬁcation (Fig. S8A). Surprisingly, in a
limited analysis using patient samples with conﬁrmed mutant
EGFRvIII status, we also found that 47.4% (9/19) of samples
coexist in both theEGFRvIIImutant andMig-6 deletion/loss (Fig.
S8B), suggesting a positive correlation between Mig-6 genomic
alteration and EGFRvIII. Notably, in the human GBM, the
mutant EGFRvIII has been found exclusively in samples with
concurrent high-amplitude wild-type EGFR focal ampliﬁcation.
In addition, EGFRvIII is known to dimerize and activate wild-type
EGFR during tumor pathogenesis (40). Therefore, whereas there
is no impact of Mig-6 on EGFRvIII degradation, the loss of Mig-6
in the context of the EGFRvIII mutant could presumably serve to
boost EGFR signaling by stabilizing of wild-type EGFR that is
coexpressed with EGFRvIII. Moreover, due to the fact that mul-
tiple receptor tyrosine kinases (RTKs) are coactivated in human
GBM (41) and the capacity of Mig-6 to regulate their signaling (8,
10), it is also conceivable that the loss of Mig-6 may function to
enable activation of RTKs other than EGFR. Phase III trials for
glioma treatment using monoclonal antibodies (mAbs) against
EGFR are currently underway. Interestingly, one potential
mechanism of the action of EGFRmAbs may involve their ability
to target the EGFR for degradation in the lysosome (42). Hence
deregulation of theEGFR trafﬁcking components, such as byMig-
6 deletion, in gliomas may also contribute toward sensitivity to
these and other future EGFR-targeted therapies. Such mecha-
nistic insights into EGFR signaling may provide a framework for
the selection of patients suitable for such trials.
Fig. 4. Mig-6 promotes EGFR localization
into late endosome and lysosome compart-
ments upon ligand induction. (A) Mig-6
colocalizes with EGFR in vesicle structures
upon EGF stimulation. U87 cells were treated
with EGF (20 ng/mL) for the indicated times
and subjected to immunoﬂuorescence stain-
ing with anti-Mig-6 (green), anti-EGFR (red),
and DAPI (blue). (Scale bar: 20 μm.) (B) Mig-6
localizes in late endosomes upon EGF treat-
ment. U87 cells were treated with EGF for 30
min and subjected to immunoﬂuorescence
staining with anti-Mig-6 (green), anti-M6PR
(red), and DAPI (blue). (Scale bar: 20 μm.) (C)
Knockdown of Mig-6 expression in U87 cells
or (D) reconstitution of Mig-6 expression in
LN319 cells shows a limited effect on the
recruitment of EGFR to early endosomes.
Cells were treated with EGF for 10 min and
subjected to immunoﬂuorescence staining
with anti-EGFR (green), anti-EEA1 (red), and
DAPI (blue). Quantiﬁcation of colocalization
between EGFR and EEA1 signals is shown in
the histograms. Error bars indicate ±SD.
(Scale bar: 20 μm.) (E) Knockdown of Mig-6
expression in U87 cells attenuates the
recruitment of EGFR to late endosomes. Cells
were treated with EGF for 30 min and sub-
jected to immunoﬂuorescence staining with
anti-EGFR (green), anti-M6PR (red), and DAPI (blue). Quantiﬁcation of colocalization between EGFR and CI-M6PR signals is shown in the histograms. Error bars
indicate ±SD (**, P = 0.001; n = 5). (Scale bar: 20 μm.) (F) Reconstitution of Mig-6 expression in LN319 cells promotes the recruitment of EGFR to late
endosomes. Cells were treated and stained as described in E. Quantiﬁcation of colocalization between EGFR and CI-M6PR signals is shown in the histograms.
Error bars indicate ±SD (*, P = 0.015; n = 5). (Scale bar: 20 μm.) (G) Knockdown of Mig-6 expression in U87 cells attenuates the recruitment of EGFR to
lysosomes. Cells were treated with EGF for 60 min and subjected to immunoﬂuorescence staining with anti-EGFR (green), anti-LAMP1 (red), and DAPI (blue).
Quantiﬁcation of colocalization between EGFR and LAMP1 signals is shown in the histograms. Error bars indicate ±SD (**, P = 0.006; n = 5). (Scale bar: 20 μm.)
(H) Reconstitution of Mig-6 expression in LN319 cells promotes the recruitment of EGFR to lysosomes. Cells were treated and stained as described in G.
Quantiﬁcation of colocalization between EGFR and LAMP1 signals is shown in the histograms. Error bars indicate ±SD (**, P = 0.006; n = 5). (Scale bar: 20 μm.)
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Materials and Methods
Cell Lines. The human glioma cell lines LN235, LN319, LN464, LNZ308, and U87
and the human embryonic kidney cell line HEK293T were purchased from
American Type Culture Collection (ATCC). Primary murine astrocytes were
isolated from 5-day-old pups with indicated genotypes and maintained in
DMEM containing 10% FBS as previously described (43, 44).
Antibodies for Immunoﬂuorescence and Western Blot Analysis. The following
antibodieswereused:Mig-6 (8); EGFR(Upstate); PDGFRβ, pAkt, pMEK, andpERK
(Cell Signaling); CI-M6RP, EEA1, and LAMP1 (Abcam); STX8 (BD Biosciences); HA
(Roche); and pEGFR Y1173 and β-actin (Santa Cruz Biotechnology).
Proliferation Assays. Proliferation assays were performed on 12-well plates in
triplicate with 10,000 cells per well. Cells were ﬁxed in 10% formalin in PBS and
stainedwithcrystalvioletat2-dayincrementsstartingaftercelladherence(day0).
At the conclusion of the assay, crystal violet was extracted with 10% acetic acid
and absorbance at 595 nmwas measured with a 96-well plate reader.
Anchorage-Independent Growth Assay. Between 5,000 and 10,000 cells per
well were seeded in medium containing 0.4% low-melting agarose on top of
bottom agar containing 1% low-melting agarose in regular medium. After
14–21 days, colonies were stained with iodonitrotetrazoliumchloride (Sigma)
and counted with Totallab TL100 software.
Cell Invasion Assay. Cell invasion assays were performed in Boyden chambers
with matrix proteins as per manufacturer’s protocol (BD Biosciences). A total
of 200,000 cells were washed and then seeded in serum-free medium. The
chemoattractant was medium plus 10% FBS.
Lentiviral-Mediated shRNA Targeting. Lentiviral shRNA clones targetingMig-6,
STX8, and nontargeting control construct shGFP were obtained from
the RNAi Consortium at the Dana-Farber/Broad Institute (sequences avail-
able upon request). Lentiviruses were produced in 293T cells with packing
mix (ViraPower Lentiviral Expression System; Invitrogen) as per manu-
facturer’s instruction.
Yeast Two-Hybrid Interaction Screening. A pretransformed human fetal brain
cDNA library (Clontech) was screened (1 × 106 clones) using the AH109 yeast
reporter strain and the Matchmaker Two-Hybrid System 3 (Clontech),
according to the manufacturer’s instructions. Plasmid DNA from 200
potential positive clones was isolated after transformation into Escherichia
coli strain DH5, followed by DNA sequencing using the provided prey vector-
speciﬁc primers. Informative sequencing data were obtained for 109 of the
200 clones, 74 of which contained partial to full-length coding sequence and
were further considered for downstream analysis.
Coimmunoprecipitation Analysis. Cells were harvested in lysis buffer consisting
of 20 mM Tris (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 10% glycerol, 1 mM
EGTA, 1 mM EDTA, 5 mM sodium pyrophosphate, 50 mM NaF, 10 mM
β-glycerophosphate, 1 mM sodium vanadate, 0.5 mM DTT, 1 mM PMSF, and
1× Protease Inhibitor Mixture (Roche). One to 1.5 mg of total protein was
incubated with 1 μg of indicated antibodies and Protein A agarose (Repli-
Gen) at 4 °C overnight with rocking. Immunoprecipitation complexes were
eluted by boiling in SDS loading buffer and resolved on NuPAGE 4–12% Bis-
Tris gels (Invitrogen) for immunoblotting analysis.
Immunoﬂuorescence Analysis. Cells were cultured on coverslips, followed by
ﬁxation for 15 min at room temperature in 4% paraformaldehyde in PBS,
Fig. 5. Mig-6 interacts with STX8 to control
EGFR trafﬁcking through late endosome. (A)
Mig-6 interacts with STX8 in vivo. U87 cell
lysates were immunoprecipitated (IP) with nor-
mal mouse IgG or with an antibody against
STX8 or Mig-6 and immunoblotted with the
indicated antibodies. *, nonspeciﬁc band. (B)
The interaction between Mig-6 and STX8 is
enhanced by EGF stimulation. U87 cells were
treated with EGF (20 ng/mL) for 30 min. Cell
lysates were subjected to IP and immunoblot-
ting as in A. (C) Complex formation between
EGFR, Mig-6, and STX8. U87 cells were treated
with EGF (20 ng/mL) for 30 min and subjected to
immunoﬂuorescence staining with anti-EGFR
(purple), anti-Mig-6 (green), anti-STX8 (red),
and DAPI (blue). (Scale bar: 20 μm.) (D) Mig-6
mediates the complex formation between EGFR
and STX8. LN319 cells expressing vector (Vec)
or Mig-6 were treated with EGF (20 ng/mL) for
30 min. Cell lysates were subjected to IP
with anti-STX8 and immunoblotted with the
indicated antibodies. (E) Knockdown of Mig-6
expression in U87 cells inhibits colocalization
between EGFR and STX8. U87 cells were treated
with EGF (20 ng/mL) for 30 min and subjected to
immunoﬂuorescence staining with anti-EGFR
(green), anti-STX8 (red), and DAPI (blue).
Quantiﬁcation of colocalization between EGFR
and STX8 signals is shown in the histograms.
Error bars indicate ±SD (**, P = 0.001; n = 5).
(Scale bar: 20 μm.) Knockdown of STX8 expres-
sion in (F) U87 cells and in (G) LN319 cells
expressing Mig-6 (LN319-Mig-6) inhibits the
recruitment of EGFR to late endosomes. Cells
were treated with EGF (20 ng/mL) for 30 min
and subjected to immunoﬂuorescence staining
with anti-EGFR (green), anti-M6PR (red), and
DAPI (blue). Quantiﬁcation of colocalization
between EGFR and CI-M6PR signals is shown in the histograms. Error bars indicate ±SD (**, P < 0.001; n = 5). (Scale bar: 20 μm.) (H) Mig-6 regulates EGFR
trafﬁcking. Upon EGF stimulation, Mig-6 is recruited to activated EGFR and suppresses EGFR downstream signaling. During the ligand-stimulated EGFR
trafﬁcking, the interaction of Mig-6 and STX8 in the late endosomes recruits STX8 to the Mig-6-EGFR complex, which ensures EGFR trafﬁcking from early
endosomes to late endosomes and subsequent degradation. Note that the continuous presence of ligand also induces the expression of Mig-6 at the
transcriptional level, which further keeps EGFR signaling in check.
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permeabilization for 5 min at room temperature in 0.1% Triton X-100 in PBS,
and blocking for 1 h at room temperature in 1% BSA in PBS. Slides were then
incubated overnight at 4 °C with indicated antibodies. Slides were stained
for 1 h at room temperature with the corresponding Alexa Fluor secondary
antibodies (Invitrogen) and mounted with mounting medium with DAPI
(Vector). Microscopic images were obtained with a Zeiss LSM 510 confocal
microscope in the Harvard NeuroDiscovery Center (HNDC) optical imaging
core, using constant exposure times for each channel in individual experi-
ment. Signal intensity and colocalization were measured with ImageJ soft-
ware. Magniﬁcation was ×630 unless otherwise indicated.
FISH. Mig-6 DNA probe was extracted from BAC clone CTD-2289F6 (Invi-
trogen) and labeled by nick translation mix (Roche). The centromere-speciﬁc
CEP1 probe (Abbott Laboratories) served as a ploidy reference. FISH signal
evaluation and acquisition were performed manually using ﬁlter sets and
software developed by Applied Spectral Imaging.
Statistical Analysis. Statistical analysis was performed using the unpaired
Student’s t test. For all experiments with error bars, standard deviation was
calculated to indicate the variation within each experiment, and values
represent mean ± SD.
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